Stopping liver cancer in its tracks

October 02, 2014

A University of Tokyo research group has discovered that AIM (Apoptosis Inhibitor of Macrophage), a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice liver cells. This discovery may lead to a therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer and the third most common cause of cancer deaths.

Professor Toru Miyazaki's group at the Laboratory of Molecular Biomedicine from Pathogenesis, in the Faculty of Medicine has shown that AIM (also known as CD5L) accumulates on the cell membrane of HCC cells, where it triggers the complement cascade, a highly efficient process of eliminating cancerized cells. Experiments showed that mice unable to produce AIM fed on a high-fat diet for a year developed multiple liver tumors. Additionally, when the same type of mice on the same diet for 45 weeks, at which point they would have already developed HCC, showed no signs of HCC after treatment with AIM, indicating that cancerous cells were being destroyed.

The group had previously found AIM, and identified its supportive role for the immune system and a protective role in obesity progression of fat cells. Now they have found that AIM is involved in eliminating cancerized cells. The group revealed that AIM accumulates on the surface of mice HCC cells, but not on normal cells and showed that AIM interferes with proteins that normally suppress the complement cascade, triggering a process that leads to necrosis and elimination of the cancerous cells.

HCC can be caused by several factors including a high-fat diet, and this form of liver cancer is increasing due to rising obesity. "Because of its resistance to chemotherapy, HCC is now the third most common cause of cancer-related deaths, and therefore, it is certainly desirable to identify the preventive machinery against HCC. The most exciting finding for us is that AIM behaves in two different ways in preventing liver diseases. It enters into normal hepatocytes to keep them skinny, which prevents the buildup of fat inside cells seen in steatosis, whereas it accumulates on the surface of HCC cells to kill them," says Professor Miyazaki. Given that AIM also gathers on the surface of human HCC, it may be possible to develop AIM as a therapy for human HCC. Professor Miyazaki continues, "It is surprising that we do have an excellent system to eliminate undesired cancer cells, and that this system may certainly be therapeutically applicable not only to HCC, but also more broadly to other types of cancer."
-end-
Journal article

Natsumi Maehara, Satoko Arai, Mayumi Mori, Yoshihiro Iwamura, Jun Kurokawa, Toshihiro Kai, Shunsuke Kusunoki, Kaori Taniguchi, Kazutaka Ikeda, Osamu Ohara, Ken-ichi Yamamura, and Toru Miyazaki, "Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation," Cell Reports 9, 1-14 (forthcoming: 9 October 2014). http://dx.doi.org/10.1016/j.celrep.2014.08.058

Links

Laboratory of Molecular Biomedicine from Pathogenesis, Center for Disease Biology and Integrative Medicine
Faculty of Medicine
The University of Tokyo

Contact information

Professor Toru Miyazaki
Laboratory of Molecular Biomedicine from Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
Email: tm@m.u-tokyo.ac.jp
Secretary: Inoue Shiho, Inoue Yukari
Email: miya@m.u-tokyo.ac.jp
Tel: +81-3-5841-1436
Fax: +81-3-5841-1438

Graduate School of Medicine press officer & contact information

Ryosuke Nobukawa
General Affairs Office
Graduate School of Medicine, The University of Tokyo
Email: ishomu@m.u-tokyo.ac.jp
Tel: +81-3-5841-3304
Fax: +81-3-5841-8585

University of Tokyo

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.